title: An avian model for the reversal of neurobehavioral teratogenicity with neural stem cells.
abstract: A fast and simple model which uses lower animals on the evolutionary scale is beneficial for developing procedures for the reversal of neurobehavioral teratogenicity with neural stem cells. Here, we established a procedure for the derivation of chick neural stem cells, establishing embryonic day (E) 10 as optimal for progression to neuronal phenotypes. Cells were obtained from the embryonic cerebral hemispheres and incubated for 5-7 days in enriched medium containing epidermal growth factor (EGF) and basic fibroblast growth factor (FGF2) according to a procedure originally developed for mice. A small percentage of the cells survived, proliferated and formed nestin-positive neurospheres. After removal of the growth factors to allow differentiation (5 days), 74% of the cells differentiated into all major lineages of the nervous system, including neurons (Beta III tubulin-positive, 54% of the total number of differentiated cells), astrocytes (GFAP-positive, 26%), and oligodendrocytes (O4-positive, 20%). These findings demonstrate that the cells were indeed neural stem cells. Next, the cells were transplanted in two allograft chick models; (1) direct cerebral transplantation to 24-h-old chicks, followed by post-transplantation cell tracking at 24 h, 6 days and 14 days, and (2) intravenous transplantation to chick embryos on E13, followed by cell tracking on E19. With both methods, transplanted cells were found in the brain. The chick embryo provides a convenient, precisely-timed and unlimited supply of neural progenitors for therapy by transplantation, as well as constituting a fast and simple model in which to evaluate the ability of neural stem cell transplantation to repair neural damage, steps that are critical for progress toward therapeutic applications.
authors.affiliation: The Ross Laboratory for Studies in Neural Birth Defects, Department of Medical Neurobiology, Institute for Medical Research - Israel-Canada, The Hebrew University-Hadassah Medical School, Box 12272, 91120 Jerusalem, Israel.
authors.forename: Sharon
authors.initials: S
authors.lastname: Dotan
authors.forename: Adi
authors.initials: A
authors.lastname: Pinkas
authors.forename: Theodore A
authors.initials: TA
authors.lastname: Slotkin
authors.forename: Joseph
authors.initials: J
authors.lastname: Yanai
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000628:therapy*; D000818:Animals; D001253:Astrocytes / Q000637:transplantation; D018929:Cell Culture Techniques; D002454:Cell Differentiation; D054022:Cerebrum / Q000196:embryology / Q000601:surgery; D002642:Chick Embryo; D004195:Disease Models, Animal; D004625:Embryo, Nonmammalian / Q000187:drug effects* / Q000601:surgery; D053595:Embryonic Stem Cells / Q000187:drug effects / Q000637:transplantation*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D009474:Neurons / Q000637:transplantation*; D009836:Oligodendroglia / Q000637:transplantation; D033581:Stem Cell Transplantation / Q000379:methods*; D018675:Toxicity Tests / Q000379:methods*
chemical_list: D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor